Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity

about

Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity

Item

http://www.wikidata.org/entity/Q56892381

description

scientific article published on 07 May 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Combination of dual mTORC1/2 i ...... tentiates anti-tumour immunity

@en

Combination of dual mTORC1/2 i ...... tentiates anti-tumour immunity

@nl

type

Item

label

Combination of dual mTORC1/2 i ...... tentiates anti-tumour immunity

@en

Combination of dual mTORC1/2 i ...... tentiates anti-tumour immunity

@nl

prefLabel

Combination of dual mTORC1/2 i ...... tentiates anti-tumour immunity

@en

Combination of dual mTORC1/2 i ...... tentiates anti-tumour immunity

@nl

P1476

Combination of dual mTORC1/2 i ...... tentiates anti-tumour immunity

@en

P2093

Anna Staniszewska

http://www.w3.org/2001/XMLSchema#string

Deanna A Mele

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Kuczynski

http://www.w3.org/2001/XMLSchema#string

Laura Jarvis

http://www.w3.org/2001/XMLSchema#string

Oona Delpuech

http://www.w3.org/2001/XMLSchema#string

Sabina Cosulich

http://www.w3.org/2001/XMLSchema#string

Sophie Langdon

http://www.w3.org/2001/XMLSchema#string

P2860

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

mTOR is a key modulator of ageing and age-related disease

mTOR regulates memory CD8 T-cell differentiation

Immune Checkpoint Blockade in Cancer Therapy

The roles of IFN gamma in protection against tumor development and cancer immunoediting

Determination of lymphocyte division by flow cytometry

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

mTOR regulation of autophagy

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.

Clinical pharmacokinetics of everolimus.

P304

e1458810

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/2162402X.2018.1458810

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-05-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30221055

http://www.w3.org/2001/XMLSchema#string

P932

6136876

http://www.w3.org/2001/XMLSchema#string